Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 87Myeloid 24Lymphoid 10Classical hematology 4Tumor-Agnostic 1Thoracic 1Sarcoma 1Plasma cell 1Dermatologic 1CNS 1

Conditions

Sarcoma, Myeloid 1Leukemia, Myeloid, Acute 1Leukemia 1Hematologic Neoplasms 1

Interventions

Specimen Handling 36Magnetic Resonance Spectroscopy 31Cyclophosphamide 28Doxorubicin 23Biopsy 22pembrolizumab 21Temozolomide 21X-Rays 17Radiotherapy 17Radiation 16Nivolumab 13fludarabine 12atezolizumab 12Vincristine 12Phantoms, Imaging 12Irinotecan 12Ifosfamide 12Gemcitabine 12cabozantinib 10Bevacizumab 9liposomal doxorubicin 8Surgical Procedures, Operative 8Paclitaxel 8Ipilimumab 8Etoposide 8Immunoglobulin G 7Carboplatin 7palbociclib 6olaparib 6fludarabine phosphate 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Azacitidine × Sarcoma × 90 days × Clear all
NCT05735184 2026-03-13

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

Kura Oncology, Inc.

Phase 1 Recruiting
420 enrolled
Other hematologic neoplasmSarcoma

Leukemia, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡